AU Patent

AU2010363814B2 — Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD).

Assigned to Gentium SRL · Expires 2016-05-19 · 10y expired

What this patent protects

Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD) in humans is disclosed, preferably in hematopoietic stem cell transplantation (HSCT), more preferably allogeneic hematopoietic stem cell transplantation. Graft versus Host Disease of the inven…

USPTO Abstract

Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD) in humans is disclosed, preferably in hematopoietic stem cell transplantation (HSCT), more preferably allogeneic hematopoietic stem cell transplantation. Graft versus Host Disease of the invention (GVHD) can be acute aGVHD and/or chronic cGVHD, preferably acute.

Drugs covered by this patent

Patent Metadata

Patent number
AU2010363814B2
Jurisdiction
AU
Classification
—
Expires
2016-05-19
Drug substance claim
No
Drug product claim
No
Assignee
Gentium SRL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.